GI Innovation's GI-101A Wins FDA Fast Track Designation for Metastatic Urothelial Carcinoma
核心洞察
GI Innovation (搜索)'s immuno-oncology candidate GI-101A received FDA Fast Track designation for metastatic urothelial carcinoma (搜索), sending shares up 5% to 8,380 won on August 26.
The designation covers patients with locally advanced or metastatic urothelial carcinoma (搜索) who have previously received immunotherapy, an area of significant unmet need.
Phase 1 data showed GI-101A combined with Keytruda achieved a 50% objective response rate and 75% disease control rate in four previously treated urothelial carcinoma patients.
GI Innovation (搜索) (358570.KQ) announced that its immuno-oncology drug candidate GI-101A has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of metastatic urothelial carcinoma (搜索). The designation covers patients with locally advanced or metastatic urothelial carcinoma who have previously received immunotherapy. On the news, the company's shares closed up 5% from the previous session at 8,380 won (approximately $6.1) on August 26, according to the Korea Exchange.
The FDA's Fast Track program supports the development of drug candidates that demonstrate the potential to address unmet medical needs in serious or life-threatening conditions. Once designated, sponsors gain access to more frequent interactions with the FDA throughout the development process and may become eligible for priority review or accelerated approval if clinical data support such pathways. In effect, the designation opens the door to potentially reducing the new drug approval review period to as little as six months.
Clinical Development Program
GI Innovation (搜索) is currently running a randomized Phase 2 trial of GI-101A in combination with Keytruda (pembrolizumab) in urothelial carcinoma patients who have failed prior immunotherapy. Patient enrollment has been ongoing since the first patient was dosed in May.
Early Efficacy Signals
Early clinical data for GI-101A have been encouraging. According to Phase 1 results presented orally by the company at the American Society of Clinical Oncology (ASCO) annual meeting in May, the combination of GI-101A and Keytruda achieved an objective response rate (ORR) of 50% and a disease control rate (DCR) of 75% in four patients with advanced or metastatic urothelial carcinoma (搜索) who had previously received immuno-oncology therapy.
The median progression-free survival for urothelial carcinoma patients who have failed immunotherapy is typically only around six months. However, among the two patients who achieved partial responses with the GI-101A and Keytruda combination, one has maintained treatment for more than two years and the other for more than seven months, according to the company.
Regulatory Momentum
"The FDA typically decides on Fast Track designation within 60 days of application submission, but GI-101A received the designation in just two weeks, which is highly encouraging," said Jang Myung-ho, CEO of GI Innovation (搜索). "With this Fast Track designation as a catalyst, we will accelerate clinical development so that GI-101A can offer new treatment opportunities to more patients."